Structural implications of β-cardiac myosin heavy chain mutations in human disease

Anatomical Record

Volumn 297, Issue 9, 2014, Pages 1670-1680

  Colegrave, Melanie ^a   Peckham, Michelle ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cardiac disease; Point mutation; Skeletal muscle disease; cardiac myosin

Indexed keywords

MOLECULAR MOTOR; MYOSIN; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 7; MYOSIN HEAVY CHAIN BETA; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 2; S 1 PROTEIN; S 2 PROTEIN; UNCLASSIFIED DRUG; CARDIAC MYOSIN; MYH7 PROTEIN, HUMAN;

ARTICLE; CRYSTAL STRUCTURE; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HEART; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; SARCOMERE; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; HEART DISEASE; METABOLISM; MOLECULAR GENETICS; MUTATION; PHENOTYPE; PROTEIN CONFORMATION; RISK FACTOR; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; CARDIAC MYOSINS; GENETIC PREDISPOSITION TO DISEASE; HEART DISEASES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; MYOSIN HEAVY CHAINS; PHENOTYPE; PROTEIN CONFORMATION; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84906080378     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22973     Document Type: Article

References (67)

1. Alamo L, Wriggers W, Pinto A, Bartoli F, Salazar L, Zhao FQ, Craig R, Padron R. 2008. Three-dimensional reconstruction of tarantula myosin filaments suggests how phosphorylation may regulate myosin activity. J Mol Biol 384:780-797.
2. Alpert NR, Mohiddin SA, Tripodi D, Jacobson-Hatzell J, Vaughn-Whitley K, Brosseau C, Warshaw DM, Fananapazir L. 2005. Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations. Am J Physiol Heart Circ Physiol 288:H1097-1102.
3. Armel TZ, Leinwand LA. 2009. Mutations in the beta-myosin rod cause myosin storage myopathy via multiple mechanisms. Proc Natl Acad Sci USA 106:6291-6296.
4. Armel TZ, Leinwand LA. 2010a. A mutation in the beta-myosin rod associated with hypertrophic cardiomyopathy has an unexpected molecular phenotype. Biochem Biophys Res Commun 391:352-356.
5. Armel TZ, Leinwand LA. 2010b. Mutations at the same amino acid in myosin that cause either skeletal or cardiac myopathy have distinct molecular phenotypes. J Mol Cell Cardiol 48:1007-1013.
6. Becker E, Navarro-Lopez F, Francino A, Brenner B, Kraft T. 2007. Quantification of mutant versus wild-type myosin in human muscle biopsies using nano-LC/ESI-MS. Anal Chem 79:9531-9538.
7. Behrmann E, Muller M, Penczek PA, Mannherz HG, Manstein DJ, Raunser S. 2012. Structure of the rigor actin-tropomyosin-myosin complex. Cell 150:327-338.
8. Belus A, Piroddi N, Scellini B, Tesi C, Amati GD, Girolami F, Yacoub M, Cecchi F, Olivotto I, Poggesi C. 2008. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J Physiol 586:3639-3644.
9. Blair E, Redwood C, de Jesus Oliveira M, Moolman-Smook JC, Brink P, Corfield VA, Ostman-Smith I, Watkins H. 2002. Mutations of the light meromyosin domain of the beta-myosin heavy chain rod in hypertrophic cardiomyopathy. Circ Res 90:263-269.
10. Blankenfeldt W, Thoma NH, Wray JS, Gautel M, Schlichting I. 2006. Crystal structures of human cardiac beta-myosin II S2-Delta provide insight into the functional role of the S2 subfragment. Proc Natl Acad Sci USA 103:17713-17717.
11. Bohlega S, Abu-Amero SN, Wakil SM, Carroll P, Al-Amr R, Lach B, Al-Sayed Y, Cupler EJ, Meyer BF. 2004. Mutation of the slow myosin heavy chain rod domain underlies hyaline body myopathy. Neurology 62:1518-1521.
12. Borchert B, Tripathi S, Francino A, Navarro-Lopez F, Kraft T. 2010. The left and right ventricle of a patient with a R723G mutation of the beta-myosin heavy chain and severe hypertrophic cardiomyopathy show no differences in the expression of myosin mRNA. Cardiol J 17:518-522.
13. Buvoli M, Buvoli A, Leinwand LA. 2012. Effects of pathogenic proline mutations on myosin assembly. J Mol Biol 415:807-818.
14. Buvoli M, Hamady M, Leinwand LA, Knight R. 2008. Bioinformatics assessment of beta-myosin mutations reveals myosin's high sensitivity to mutations. Trends Cardiovasc Med 18:141-149.
15. Cuda G, Fananapazir L, Epstein ND, Sellers JR. 1997. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res cell Motil 18:275-283.
16. Cullup T, Lamont PJ, Cirak S, Damian MS, Wallefeld W, Gooding R, Tan SV, Sheehan J, Muntoni F, Abbs S, Sewry CA, Dubowitz V, Laing NG, Jungbluth H. 2012. Mutations in MYH7 cause Multi-minicore Disease (MmD) with variable cardiac involvement. Neuromuscul Disord 22:1096-1104.
17. Di Domenico M, Casadonte R, Ricci P, Santini M, Frati G, Rizzo A, Carratelli CR, Lamberti M, Parrotta E, Quaresima B, Faniello CM, Costanzo F, Cuda G. 2012. Cardiac and skeletal muscle expression of mutant beta-myosin heavy chains, degree of functional impairment and phenotypic heterogeneity in hypertrophic cardiomyopathy. J Cell Physiol 227:3471-3476.
18. Dominguez R, Freyzon Y, Trybus KM, Cohen C. 1998. Crystal structure of a vertebrate smooth muscle myosin motor domain and its complex with the essential light chain: visualization of the pre-power stroke state. Cell 94:559-571.
19. Elliott P, McKenna WJ. 2004. Hypertrophic cardiomyopathy. Lancet 363:1881-1891.
20. Flashman E, Watkins H, Redwood C. 2007. Localization of the binding site of the C-terminal domain of cardiac myosin-binding protein-C on the myosin rod. Biochem J 401:97-102.
21. Force T, Bonow RO, Houser SR, Solaro RJ, Hershberger RE, Adhikari B, Anderson ME, Boineau R, Byrne BJ, Cappola TP, Kalluri R, LeWinter MM, Maron MS, Molkentin JD, Ommen SR, Regnier M, Tang WH, Tian R, Konstam MA, Maron BJ, Seidman CE. 2010. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation 122:1130-1133.
22. Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. 1990. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62:999-1006.
23. Grabarek Z. 2011. Insights into modulation of calcium signaling by magnesium in calmodulin, troponin C and related EF-hand proteins. Biochim Biophys Acta 1813:913-921.
24. Greenberg MJ, Kazmierczak K, Szczesna-Cordary D, Moore JR. 2010. Cardiomyopathy-linked myosin regulatory light chain mutations disrupt myosin strain-dependent biochemistry. Proc Natl Acad Sci USA 107:17403-17408.
25. Gruen M, Gautel M. 1999. Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C. J Mol Biol 286:933-949.
26. Hamady M, Buvoli M, Leinwand LA, Knight R. 2010. Estimate of the abundance of cardiomyopathic mutations in the beta-myosin gene. Int J Cardiol 144:124-126.
27. Ho CY. 2012. Hypertrophic cardiomyopathy in 2012. Circulation 125:1432-1438.
28. Hoedemaekers YM, Cohen-Overbeek TE, Frohn-Mulder IM, Dooijes D, Majoor-Krakauer DF. 2013. Prenatal ultrasound diagnosis of MYH7 non-compaction cardiomyopathy. Ultrasound Obstet Gynecol 41:336-339.
29. Houdusse A, Kalabokis VN, Himmel D, Szent-Gyorgyi AG, Cohen C. 1999. Atomic structure of scallop myosin subfragment S1 complexed with MgADP: a novel conformation of the myosin head. Cell 97:459-470.
30. Houdusse A, Szent-Gyorgyi AG, Cohen C. 2000. Three conformational states of scallop myosin S1. Proc Natl Acad Sci USA 97:11238-11243.
31. Jung HS, Komatsu S, Ikebe M, Craig R. 2008. Head-head and head-tail interaction: a general mechanism for switching off myosin II activity in cells. Mol Biol Cell 19:3234-3242.
32. Kamisago M, Schmitt JP, McNamara D, Seidman C, Seidman JG. 2006. Sarcomere protein gene mutations and inherited heart disease: a beta-cardiac myosin heavy chain mutation causing endocardial fibroelastosis and heart failure. Novartis Found Symp 274:176-189; discussion 189-195, 272-176.
33. Keller DI, Coirault C, Rau T, Cheav T, Weyand M, Amann K, Lecarpentier Y, Richard P, Eschenhagen T, Carrier L. 2004. Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol 36:355-362.
34. Kerrick WG, Kazmierczak K, Xu Y, Wang Y, Szczesna-Cordary D. 2009. Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice. FASEB J 23:855-865.
35. Laing NG, Ceuterick-de Groote C, Dye DE, Liyanage K, Duff RM, Dubois B, Robberecht W, Sciot R, Martin JJ, Goebel HH. 2005. Myosin storage myopathy: slow skeletal myosin (MYH7) mutation in two isolated cases. Neurology 64:527-529.
36. Lamont PJ, Udd B, Mastaglia FL, de Visser M, Hedera P, Voit T, Bridges LR, Fabian V, Rozemuller A, Laing NG. 2006. Laing early onset distal myopathy: slow myosin defect with variable abnormalities on muscle biopsy. J Neurol Neurosurg Psychiatry 77:208-215.
37. Lossie J, Ushakov DS, Ferenczi MA, Werner S, Keller S, Haase H, Morano I. 2012. Mutations of ventricular essential myosin light chain disturb myosin binding and sarcomeric sorting. Cardiovasc Res 93:390-396.
38. Malinchik S, Cuda G, Podolsky RJ, Horowits R. 1997. Isometric tension and mutant myosin heavy chain content in single skeletal myofibers from hypertrophic cardiomyopathy patients. J Mol Cell Cardiol 29:667-676.
39. Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, Deal BJ, Driscoll DJ, Estes NA, III, Araujo CG, Liang DH, Mitten MJ, Myerburg RJ, Pelliccia A, Thompson PD, Towbin JA, Van Camp SP, Working Groups of the American Heart Association Committee on Exercise CR, Prevention, Councils on Clinical C, Cardiovascular Disease in the Y. 2004. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 109:2807-2816.
40. Marston SB. 2011. How do mutations in contractile proteins cause the primary familial cardiomyopathies? J Cardiovasc Transl Res 4:245-255.
41. McNally EM, Golbus JR, Puckelwartz MJ. 2013. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 123:19-26.
42. Montag J, Tripathi S, Kohler J, Sebastian DE, Seebohm B., List D, Faramarz M, Perrot A, A, Celim O, Francino A, Navarro-Lopez F, McKenna WJ, van der Velden J, Brenner B, Theresia T. 2014. Familial hypertrophic cardiomyopathy: unequal expression of mutant and wildtype myosin in individual myocytes as trigger for functional impairment of the heart? Biophys J 106:644A.
43. Nier V, Schultz I, Brenner B, Forssmann W, Raida M. 1999. Variability in the ratio of mutant to wildtype myosin heavy chain present in the soleus muscle of patients with familial hypertrophic cardiomyopathy. A new approach for the quantification of mutant to wildtype protein. FEBS Lett 461:246-252.
44. Obermann WM, Gautel M, Weber K, Furst DO. 1997. Molecular structure of the sarcomeric M band: mapping of titin and myosin binding domains in myomesin and the identification of a potential regulatory phosphorylation site in myomesin. EMBO J 16:211-220.
45. Ochala J, Li M, Ohlsson M, Oldfors A, Larsson L. 2008. Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation. J Physiol 586:2993-3004.
46. Offer G. 1990. Skip residues correlate with bends in the myosin tail. J Mol Biol 216:213-218.
47. Onishi H, Mikhailenko SV, Morales MF. 2006. Toward understanding actin activation of myosin ATPase: the role of myosin surface loops. Proc Natl Acad Sci USA 103:6136-6141.
48. Palmiter KA, Tyska MJ, Haeberle JR, Alpert NR, Fananapazir L, Warshaw DM. 2000. R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J Muscle Res cell Motil 21:609-620.
49. Parry DA, Fraser RD, Squire JM. 2008. Fifty years of coiled-coils and alpha-helical bundles: a close relationship between sequence and structure. J Struct Biol 163:258-269.
50. Peckham M. 2011. Coiled coils and SAH domains in cytoskeletal molecular motors. Biochem Soc Trans 39:1142-1148.
51. Pezzoli L, Sana ME, Ferrazzi P, Iascone M. 2012. A new mutational mechanism for hypertrophic cardiomyopathy. Gene 507:165-169.
52. Rayment I, Rypniewski WR, Schmidt-Base K, Smith R, Tomchick DR, Benning MM, Winkelmann DA, Wesenberg G, Holden HM. 1993. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 261:50-58.
53. Redwood CS, Moolman-Smook JC, Watkins H. 1999. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res 44:20-36.
54. Revera M, van der Merwe L, Heradien M, Goosen A, Corfield VA, Brink PA, Moolman-Smook JC. 2008. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. Cardiovasc Res 77:687-694.
55. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5:725-738.
56. Sellers JR, Knight PJ. 2007. Folding and regulation in myosins II and V. J Muscle Res Cell Motil 28:363-370.
57. Shingde MV, Spring PJ, Maxwell A, Wills EJ, Harper CG, Dye DE, Laing NG, North KN. 2006. Myosin storage (hyaline body) myopathy: a case report. Neuromuscul Disord 16:882-886.
58. Smith CA, Rayment I. 1995. X-ray structure of the magnesium(II)-pyrophosphate complex of the truncated head of Dictyostelium discoideum myosin to 2.7 A resolution. Biochemistry 34:8973-8981.
59. Smith CA, Rayment I. 1996. Active site comparisons highlight structural similarities between myosin and other P-loop proteins. Biophys J 70:1590-1602.
60. Taylor MR, Carniel E, Mestroni L. 2006. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 1:27.
61. Tripathi S, Schultz I, Becker E, Montag J, Borchert B, Francino A, Navarro-Lopez F, Perrot A, Ozcelik C, Osterziel KJ, McKenna WJ, Brenner B, Kraft T. 2011. Unequal allelic expression of wild-type and mutated beta-myosin in familial hypertrophic cardiomyopathy. Basic Res Cardiol 106:1041-1055.
62. Uyeda TQ, Ruppel KM, Spudich JA. 1994. Enzymatic activities correlate with chimaeric substitutions at the actin-binding face of myosin. Nature 368:567-569.
63. van Engelen K, Postma AV, van de Meerakker JB, Roos-Hesselink JW, Helderman-van den Enden AT, Vliegen HW, Rahman T, Baars MJ, Sels JW, Bauer U, Pickardt T, Sperling SR, Moorman AF, Keavney B, Goodship J, Klaassen S, Mulder BJ. 2013. Ebstein's anomaly may be caused by mutations in the sarcomere protein gene MYH7. Neth Heart J 21:113-117.
64. Witjas-Paalberends ER, Piroddi N, Stam K, van Dijk SJ, Oliviera VS, Ferrara C, Scellini B, Hazebroek M, ten Cate FJ, van Slegtenhorst M, dos Remedios C, Niessen HW, Tesi C, Stienen GJ, Heymans S, Michels M, Poggesi C, van der Velden J. 2013. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovasc Res 99:432-441.
65. Wolny M, Colegrave M, Colman L, White E, Knight PJ, Peckham M. 2013. Cardiomyopathy mutations in the tail of beta-cardiac myosin modify the coiled-coil structure and affect integration into thick filaments in muscle sarcomeres in adult cardiomyocytes. J Biol Chem 288:31952-31962.
66. Yamashita H, Tyska MJ, Warshaw DM, Lowey S, Trybus KM. 2000. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. J Biol Chem 275:28045-28052.
67. Zoghbi ME, Woodhead JL, Moss RL, Craig R. 2008. Three-dimensional structure of vertebrate cardiac muscle myosin filaments. Proc Natl Acad Sci USA 105:2386-2390.